Academic Journal
Q1Journal of Thoracic Oncology
About Journal of Thoracic Oncology
Journal of Thoracic Oncology is a scholarly journal published by Elsevier Inc.. SCImago 2025 places it in Q1 with an SJR of 7.497 and an H-index of 204.
Its listed coverage is 2006-2026 and its research categories include Medicine (miscellaneous) (Q1); Oncology (Q1); Pulmonary and Respiratory Medicine (Q1). The 2025 dataset reports 313 documents and 6029 citations across the latest three-year reporting window.
The Journal of Thoracic Oncology (JTO) is a prestigious peer-reviewed medical journal dedicated to the field of thoracic oncology. As one of the leading publications in oncology, it plays a vital role in disseminating cutting-edge research, clinical advancements, and critical insights related to the diagnosis, treatment, and management of thoracic cancers, particularly lung cancer.
Scope and Focus of the Journal
The Journal of Thoracic Oncology publishes original research articles, reviews, clinical studies, and editorials focused on thoracic cancers, which include lung cancer, mesothelioma, and other malignancies affecting the chest. The journal's scope covers a wide range of topics, including molecular biology, immunotherapy, targeted therapies, diagnostic methods, and epidemiology. As thoracic oncology continues to evolve, JTO serves as a central hub for the latest breakthroughs and developments in the field.
Impact on the Medical Community
Lung cancer is one of the most common and deadly cancers worldwide, contributing to significant global morbidity and mortality. The Journal of Thoracic Oncology plays an essential role in raising awareness, fostering collaboration among healthcare professionals, and advancing the treatment landscape for thoracic cancer patients. The journal highlights studies on precision medicine, including the identification of biomarkers that predict response to therapies, and the development of novel drugs and therapeutic strategies.
As the treatment paradigm for lung cancer shifts toward personalized approaches, JTO helps physicians stay updated on the latest evidence-based practices and clinical trials. The journal provides clinicians with the necessary tools to make informed decisions, ultimately improving patient outcomes and quality of life.
Editorial Excellence and Collaboration
The Journal of Thoracic Oncology has a distinguished editorial board composed of leading experts in thoracic oncology from around the globe. This expert team ensures that the journal maintains high standards of scientific rigor and clinical relevance. The editorial process focuses on publishing studies that are methodologically sound and contribute meaningfully to the body of knowledge in thoracic oncology.
Moreover, JTO encourages collaboration between academic researchers, clinicians, and industry professionals, facilitating a comprehensive understanding of thoracic cancers and fostering interdisciplinary research. The journal also publishes content related to the socioeconomic and psychological aspects of lung cancer, addressing the multifaceted nature of the disease.
Key Topics Covered in the Journal
Some of the key topics explored in the Journal of Thoracic Oncology include:
-
Lung Cancer Epidemiology: Understanding trends, risk factors, and global statistics.
-
Molecular and Genetic Research: Identifying genetic mutations and molecular mechanisms involved in thoracic cancers.
-
Immunotherapy and Targeted Therapies: Investigating the role of immune checkpoint inhibitors and targeted drugs in treatment.
-
Early Detection and Diagnosis: Advancing techniques such as liquid biopsy and imaging methods to diagnose lung cancer at an earlier stage.
-
Clinical Trials: Reporting the latest results from clinical trials exploring new therapies and treatment regimens.
-
Palliative Care and Quality of Life: Addressing the challenges faced by patients undergoing treatment, including symptom management and psychosocial support.
Why Subscribe to the Journal of Thoracic Oncology?
For researchers, clinicians, and healthcare professionals involved in thoracic oncology, subscribing to the Journal of Thoracic Oncology is invaluable. The journal provides timely access to the latest research and clinical innovations, helping practitioners stay ahead of the curve in the evolving landscape of thoracic cancer treatment. Furthermore, JTO's open-access platform ensures that vital research is accessible to a global audience, improving healthcare outcomes worldwide.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Journal of Thoracic Oncology (JTO) serves as a critical publication platform for the global oncology community, specifically focused on thoracic cancer research, treatment, and clinical advancements. As the official journal of the International Association for the Study of Lung Cancer (IASLC), JTO has become a premier resource for oncologists, researchers, and healthcare professionals involved in the diagnosis and management of lung cancer and other thoracic malignancies. With an emphasis on translational research and innovative therapeutic strategies, JTO provides a comprehensive and up-to-date overview of the field’s most significant breakthroughs.
1. Focus on Lung Cancer Research and Treatment
Lung cancer remains one of the most prevalent and deadly cancers worldwide. JTO is dedicated to the exploration of novel therapies, early detection methods, and understanding the complex biology of lung cancer. The journal publishes high-impact articles related to non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and other thoracic cancers. Through in-depth studies, clinical trials, and evidence-based approaches, JTO aims to contribute valuable insights to improve patient outcomes and survival rates.
2. Cutting-Edge Clinical Research
The Journal of Thoracic Oncology emphasizes the importance of clinical research in advancing the treatment of thoracic cancers. It features articles on the latest clinical trials, pharmacological developments, immunotherapy innovations, and precision medicine in thoracic oncology. By prioritizing evidence from randomized controlled trials and large-scale studies, JTO ensures that the content it publishes adheres to the highest standards of scientific rigor, offering oncologists and healthcare providers vital information to guide treatment decisions.
3. Translational Research and Molecular Oncology
One of the journal's defining features is its focus on the molecular and genetic aspects of thoracic cancers. JTO explores the genetic mutations, molecular markers, and signaling pathways that drive lung cancer progression. Research on liquid biopsies, targeted therapies, and personalized medicine is integral to the journal's content. By focusing on translational research, JTO bridges the gap between laboratory discoveries and clinical applications, helping to translate cutting-edge science into practical solutions for patient care.
4. Multidisciplinary Approach to Thoracic Oncology
Thoracic cancer treatment requires a multidisciplinary approach involving medical oncologists, surgeons, radiologists, pathologists, and pulmonologists. JTO promotes collaboration across these disciplines, fostering a comprehensive understanding of lung cancer management. By featuring research on surgical techniques, radiotherapy advancements, and multimodal therapies, JTO highlights the collaborative nature of thoracic oncology and the need for integrated care in improving patient outcomes.
5. Global Perspective and Impact
The Journal of Thoracic Oncology is recognized internationally as a leading resource in thoracic cancer research. It provides a platform for researchers, clinicians, and healthcare professionals worldwide to share findings and discuss emerging trends in thoracic oncology. JTO’s global reach ensures that the latest advancements in lung cancer research are accessible to a diverse audience, encouraging the exchange of ideas and fostering international collaboration in the fight against lung cancer.
6. Educational Content and Resources
Beyond original research articles, JTO also includes educational content such as reviews, editorials, and opinion pieces from experts in the field. These resources help professionals stay updated on evolving best practices, treatment protocols, and emerging technologies in thoracic oncology. Additionally, the journal provides insights into the psychosocial aspects of cancer care, ensuring that all facets of patient well-being are addressed in clinical practice.
Recent Research Articles
Latest publications matched automatically by ISSN.
Incorporation of Nonanatomic Histologic Factors Into a Staging System for Lung Cancer: Now Is the Time?
Yu Zhi Zhang, Andrew G. Nicholson
2026-09 · DOI: 10.1016/j.jtho.2026.103982Letter to the Editor Regarding “Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial”
Sheng Yu, Xiushen Wang, Hong Ge
2026-09 · DOI: 10.1016/j.jtho.2026.103738Corrigendum to ‘Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial’ [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R. Spigel, Jian Fang, Yuanbin Chen et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103964Implications of Clinical and Genetic Management of Subjects With BAP1 Germline Variants
Elizabeth Casey West, Filippo Lococo, Luigi Boccuto
2026-09 · DOI: 10.1016/j.jtho.2026.01.004Re-Evaluating the Impact of KRAS Mutations in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy
Sho Todo, Mariko Muto-Ishizuka, Asahi Oka, Keiichiro Kitahama et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103945Board of Directors
2026-09 · DOI: 10.1016/s1556-0864(26)00583-6In This Issue
2026-09 · DOI: 10.1016/j.jtho.2026.104088Table of Contents
2026-09 · DOI: 10.1016/s1556-0864(26)00585-xMeeting Announcements
2026-09 · DOI: 10.1016/s1556-0864(26)00584-8In the Era of Neoadjuvant Chemo-Immunotherapy for Resectable Locally Advanced Stage III NSCLC, Neoadjuvant Chemoradiotherapy Is No Longer a Standard of Care
Bianca Battilana, Matthias Guckenberger, Andreas Wicki, Isabelle Opitz et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103946Endobronchial Ultrasound-Guided Biopsy-Derived Lung Cancer Models: A Platform for Precision Therapy
Takamasa Koga, Hiroyuki Ogawa, Nikolina Radulovich, Nhu-An Pham et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103893Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
Federico Monaca, Igor Gomez-Randulfe, Javier Torres-Jiménez, Muskan Agarwal et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103726NSCLC in Vulnerable and Special Populations: Toward Personalized Care
Claudia Parisi, Andrea De Giglio, Marco Banini, Marco Tagliamento et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103705The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective
Barliz Waissengrin, Marco Tagliamento, Kamya Sankar, Karen L. Reckamp et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103957Editorial Board
2026-09 · DOI: 10.1016/s1556-0864(26)00582-4SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China
Shun Lu, Jian Fang, Yan Yu, Yun Fan et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103713Will the Pauper (Deulorlatinib/TGRX-326) Take the CROWN From the Prince (Lorlatinib) in an Alternate Ending? Deuteration Is Here to Stay in Oncology
Vivian Thuy Tieu, Emily Chou, Misako Nagasaka, Sai-Hong Ignatius Ou et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103954Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial
Jie Huang, Gang Chen, Zhehai Wang, Wenjian Jin et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103737Author Reply: Re-Evaluating the Impact of KRAS Mutations in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy
Nikhil P. Mankuzhy, Valentina Santo, Biagio Ricciuti, Narek Shaverdian et al.
2026-09 · DOI: 10.1016/j.jtho.2026.103979Optimizing First-Line Combination Treatment for EGFR-Mutated NSCLC: Does One Size Fit All?
Yi-Chen Zhang, Yi-Long Wu, Hai-Yan Tu
2026-09 · DOI: 10.1016/j.jtho.2026.103981Reviews
Community Reviews
Version History
April 14, 2025 at 4:49 pm
April 14, 2025